Targeted Cancer Drugs Could Replace Chemotherapy for Some Patients

Advances in antibody-drug conjugates (ADCs) suggest they could replace traditional chemotherapy for some cancers, offering targeted treatment with fewer side effects. Major pharmaceutical companies are developing and refining ADCs, with some already approved for specific cancers, and ongoing trials aim to expand their use. Despite challenges like toxicity and effectiveness variability, innovations in ADC design and combination therapies are promising, potentially transforming cancer treatment in the coming years.